Introduction to the target mechanism and mechanism of action of Sorafenib

Sorafenib is an oral multi-target tyrosine kinase inhibitor widely used in the treatment of solid tumors such as hepatocellular carcinoma, renal cell carcinoma and thyroid cancer. Its mechanism of action is mainly to exert anti-tumor effects by simultaneously inhibiting signaling pathways related to the proliferation and angiogenesis of multiple tumor cells.

Sorafenib blocks proliferation signaling in tumor cells and slows down cell division and expansion by inhibiting key kinases Raf-1 and B-Raf in the Raf/MEK/ERK pathway. This signaling pathway is abnormally activated in a variety of cancers and is one of the important reasons for continued cell proliferation. Therefore, sorafenib has a direct effect on inhibiting the growth of cancer cells.

Sorafenib can also effectively inhibit a variety of angiogenesis-related receptor tyrosine kinases, includingVEGFR (vascular endothelial growth factor receptor)1 , 2 and 3, and PDGFR (platelet-derived growth factor receptor). These targets control the formation of tumor blood vessels, and sorafenib intervention can cut off the tumor's supply of nutrients and oxygen, indirectly inhibiting tumor progression and metastasis.

Sorafenib can also inhibit other tyrosine kinases such as FLT3, RET and c-KIT. These kinases are abnormally expressed in certain types of leukemias and solid tumors, further expanding the anti-cancer spectrum of sorafenib. Because of its broad targeting mechanism, sorafenib has become one of the important treatment options for a variety of refractory solid tumors.

Reference materials:https://www.drugs.com/

xa0